Rheumatoid Arthritis, or RA, is an inflammatory, autoimmune disorder that begins by harming joints and ligaments and attacking the body’s own tissues. RA is characterized by joint and muscle pain, aches, and stiffness, fatigue, and fever. It is also thought to be hereditary in some cases. Those with RA are thought to be at risk for other conditions, such as heart attacks, carpal tunnel syndrome, chest pain, difficulty breathing, corneal abrasions, and Sjögren’s syndrome (ear/mouth dryness).
HBOT can improve dysexecutive functions, psychiatric symptoms (depression, anxiety and somatisation), pain interference symptoms and fatigue of patients suffering from post-COVID condition.
Restoration of glutathione levels in COVID-19 patients would be a promising approach for the management of the novel coronavirus SARS-CoV-2.
The administration of intravenous injection significantly improved the inflammation and immune situation in severe COVID-19 patients.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.